Back to search results

Ketamine for Psychiatric Disorders: Understanding Brain Activity and Dissociation

This study is looking at how Ketamine Hydrochloride, an FDA-approved medicine, affects brain activity and causes dissociative symptoms (feeling detached from your body or surroundings). Researchers want to understand these changes, especially in people with psychiatric disorders. You might be able to join if you are an inpatient at Stanford Medical Center, are over 18, and, if female, use an effective method of birth control. The main goal is to measure how many participants experience dissociative events during ketamine treatment, using a specific rating scale, within one week. The study aims to enroll about 120 participants.

Study design
This interventional study plans to enroll 120 participants. It is designed to record the effects of Ketamine Hydrochloride on brain activity.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be assessed for dissociative events for up to 1 week.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05962424

HNC: Human Neural Circuits Electrophysiology During Cognition

Recruiting
PHASE1Ages 18+InterventionalBasic science
Stanford University
~120 participants
Updated 2026-04-22 on ClinicalTrials.gov
What's tested:Ketamine Hydrochloride

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with dissociative events during ketamine infusion as assessed by CADSS (Clinician-Administered Dissociative State Scale)
Measured over up to 1 week

Conditions

Psychiatric Disorder

Explore related trials

Psychiatric Disorder

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Karl Deisseroth, MD, PhD · PRINCIPAL_INVESTIGATOR · Stanford University

Who to contact

Arjay Cordero
[email protected]
650-580-9000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient in clinical neuro inpatient units at Stanford Medical Center
Age \>18 years old
Female participants are expected to use an effective method of birth control throughout the study which includes: hormonal methods (birth control pills, patches, injections, vaginal ring or implants), barrier methods (condom or diaphragm) used with spermicide, intrauterine device (IUD), or abstinence (no sex)

Exclusion

Lifetime psychotic disorder
Pregnant or nursing females
Prior adverse ketamine response
Use of ketamine in past 7 days

What this trial measures

  • Number of participants with dissociative events during ketamine infusion as assessed by CADSS (Clinician-Administered Dissociative State Scale)up to 1 week

    The CADSS is an instrument for the measurement of dissociative symptoms. The CADSS comprises 23 subjective items and participant's responses are coded on a 5-point scale (0 = Not at all; 4 = Extreme). The higher the number on the CADSS, the more severe the symptoms.